Literature DB >> 7510664

Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.

A M Malygin1, K Somersalo, T Timonen.   

Abstract

Bispecific heteroconjugated F(ab')2 fragments were prepared from pepsin-digested monoclonal OKT3 (anti-CD3) and 3G8 (anti-CD16) antibodies with 5,5'-dithiobis- (2-nitrobenzoic acid). When these bispecific antibodies (BsA) were added to peripheral blood lymphocyte (PBL) cultures with 100 U/ml human recombinant interleukin-2 (rIL-2), preferable growth of natural killer cells occurred. After 3 weeks the frequencies of CD56+ and CD56+3- cells in cultures with BsA were 74 +/- 7% and 65 +/- 7%, respectively, compared with 48 +/- 6% and 29 +/- 7% in control cultures. The frequencies of CD3+ lymphocytes in the presence of BsA, cells from 1-day cultures were labelled with fluorescein isothiocyanate (FITC)-conjugated anti-CD3, CD4 and CD8 monoclonal antibodies (mAb) and propidium iodide which stains dead cells. Flow cytometry revealed that more than 95% of the dead cells in cultures with BsA were CD3+. Thirty-seven per cent of CD3+, 43% of CD4+ and 17% of CD8+ cells were dead on day 1, and after 3 days the CD4+/CD8+ ratio among viable lymphocytes was 1.6 in the control and 0.5 in BsA cultures. Taken together, these results show that bispecific (anti-CD3 x anti-CD16) F(ab')2 fragments are strongly immunomodulatory by inducing the killing of T cells by CD16+ cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510664      PMCID: PMC1422283     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Targeting of T-B interaction using heteroconjugate antibody.

Authors:  J L Davignon; M Vallin-Davignon; P L Cohen; R A Eisenberg
Journal:  Immunology       Date:  1991-05       Impact factor: 7.397

2.  Selective reduction and proliferation of the CD4+ and CD8+ T cell subsets with bispecific monoclonal antibodies: evidence for inter-T cell-mediated cytolysis.

Authors:  J T Wong; R B Colvin
Journal:  Clin Immunol Immunopathol       Date:  1991-02

3.  Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets.

Authors:  L T Lebow; B Bonavida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 4.  Lymphocyte-mediated responses: activation of, and lysis by, cytotoxic lymphocytes.

Authors:  R L Bolhuis; E Braakman
Journal:  Curr Opin Immunol       Date:  1988-12       Impact factor: 7.486

5.  Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients.

Authors:  V Daniel; K Schimpf; G Opelz
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

Review 6.  An in-vitro model for tumor immunotherapy with antibody heteroconjugates.

Authors:  G Jung; H J Eberhard
Journal:  Immunol Today       Date:  1988-09

7.  On the fragmentation of monoclonal IgG1, IgG2a, and IgG2b from BALB/c mice.

Authors:  P Parham
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

8.  Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.

Authors:  J T Wong; C E Pinto; J D Gifford; J T Kurnick; R L Kradin
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

9.  Targeted cytotoxic cells in human peripheral blood lymphocytes.

Authors:  M A Garrido; P Perez; J A Titus; M J Valdayo; D F Winkler; S A Barbieri; J R Wunderlich; D M Segal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

10.  Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.

Authors:  D Mezzanzanica; S Canevari; S Ménard; S M Pupa; E Tagliabue; A Lanzavecchia; M I Colnaghi
Journal:  Int J Cancer       Date:  1988-04-15       Impact factor: 7.396

View more
  2 in total

1.  Expansion and activation of natural killer cells from PBMC for immunotherapy of hepatocellular carcinoma.

Authors:  Bao-Gang Peng; Li-Jian Liang; Qiang He; Jie-Fu Huang; Ming-De Lu
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

2.  The bi-specific CD3 x NCAM antibody: a model to preactivate T cells prior to tumour cell lysis.

Authors:  M Jensen; K Ernestus; J Kemshead; M Klehr; M S Von Bergwelt-Baildon; T Schinköthe; J L Schultze; F Berthold
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.